• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

67
4
4
4
2

COUNTRY

4
1
1

PRICE

3
7
10
83

PUBLISHED

0
4
8
83

PRODUCT TYPE

81
2

Lung Cancer

(83 Products)

Lung cancer is the most common cause of cancer-related death in men and women around the world, accounting for well over a million deaths every year. Unsurprisingly therefore, keen competition exists among the world’s leading pharmaceuticals and niche players. The Lung Cancer Section features expert reports exploring markets and the competitive landscape for drugs, therapeutics, medical technologies, biomarkers, etc. worldwide; the epidemiology of lung cancer including risk factors and current/future mortality rates; as well as disease specific reports featuring advanced lung cancer, small-cell lung cancer and non-small-cell lung cancer. Whether you are looking to invest or expand into the lung cancer pharmaceutical market, sourcing a new provider or simply looking for the latest market data, your search begins here… Show Less Read more

Global Small Cell Lung Cancer Therapeutics Market 2015-2019

About Small Cell Lung Cancer Cancer occurs when, after cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in developed and...

March 2015
FROM

Global Lung Cancer Therapeutics Market 2015-2019

About Lung Cancer Cancer occurs when, after undergoing cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in both developed...

November 2014
FROM

Global Non-small Cell Lung Cancer Market 2014-2018

About Non-small Cell Lung Cancer Non-small cell lung cancer occurs when normal cells grow and multiply without control after undergoing a cell transformation. Lung cancer is the leading cause of cancer...

September 2014
FROM

Lung cancer Pipeline Highlights - 2015

The latest report Lung cancer Pipeline Highlights – 2015 Update, provides most up-to-date information on key pipeline molecules in the global Lung cancer market. It covers emerging therapies for Lung...

July 2015
FROM

Non-Small Cell Lung Cancer Pipeline Highlights - 2015

The latest report Non-Small Cell Lung Cancer Pipeline Highlights – 2015 Update, provides most up-to-date information on key pipeline molecules in the global Non-Small Cell Lung Cancer market. It covers...

July 2015
FROM

Small Cell Lung Cancer Pipeline Highlights - 2015

The latest report Small Cell Lung Cancer Pipeline Highlights – 2015 Update, provides most up-to-date information on key pipeline molecules in the global Small Cell Lung Cancer market. It covers emerging...

July 2015
FROM

Lung Cancer Drug Pipeline Update 2015

Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers. High unmet needs still persist for this tumor type and despite two decades of extensive R&D...

June 2015
FROM

Lung Cancer Drug Pathway Analyzer 2015

Extra value: One year of free online updates included with this product There are today at least 548 targeted molecular therapies known to affect more than 257 specific intracellular signaling pathways...

January 2015
FROM

Analytical Tool - Lung Cancer

Analytical Tool - Lung Cancer is a premium combo product of "Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market" and "Lung Cancer Drug Pipeline Update 2014". According...

March 2014

Lung Cancer Clinical Trial Overview

This report provides insight into the current clinical trial activity surrounding lung cancer by examining industry-sponsored activities and quantifying important development milestones and trial metrics: -...

March 2014
FROM

Europe Lung Cancer Drug Pipeline Analysis

The most common type of cancer in terms of incidence and mortality rate is Lung cancer Lung cancer is a disease in which the lining of the cell of the lung tissue has an uncontrollable growth which...

January 2014
FROM

US Lung Cancer Drug Pipeline Analysis

The most common type of cancer in terms of incidence and mortality rate is Lung cancer Lung cancer is a disease in which the lining of the cell of the lung tissue has an uncontrollable growth which...

November 2013
FROM

Stereotactic Body Radiation Therapy: Lung Cancer

The ten chapters of this book provide a concise overview of the various aspects of stereotactic body radiation therapy for non-small-cell lung cancer (NSCLC), including general, radiobiological, technical...

August 2013

Personalized Management of Lung Cancer

Lung cancer remains the leading cause of death from cancer in developed countries worldwide. Current efforts in combating lung cancer focus on the development of therapies tailored to each individual...

August 2013

Triple Analysis: Breast Cancer, Lung Cancer and Melanoma

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lung Cancer and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in...

June 2013
FROM

Triple Analysis: Colorectal Cancer, Lung Cancer and Melanoma

This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Lung Cancer and Melanoma. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM

Triple Analysis: Leukemia, Lung Cancer and Melanoma

This triple analysis focuses on cancer drug development strategies in Leukemia, Lung Cancer and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a five...

June 2013
FROM

Triple Analysis: Lung Cancer, Lymphoma and Melanoma

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Lymphoma and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a five...

June 2013
FROM

Triple Analysis: Lung Cancer, Melanoma and Pancreatic Cancer

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Melanoma and Pancreatic Cancer. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM

Triple Analysis: Lung Cancer, Melanoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Loading Indicator

Our Clients

Varian Medical Systems, Inc. Bayer AG Bristol-Myers Squibb Amgen Inc. Almac Diagnostics Group Boston Biomedical Inc.